How Takeda’s CEO transformed the company into a global pharma powerhouse

How Takeda’s CEO transformed the company into a global pharma powerhouse


Takeda Pharmaceuticals, Japan’s largest drugmaker, has undergone a sweeping transformation under CEO Christophe Weber, emerging as one of the world’s leading pharmaceutical companies.

Takeda Pharmaceuticals, Japan’s largest drugmaker, has undergone a sweeping transformation under CEO Christophe Weber, emerging as one of the world’s leading pharmaceutical companies.  

The company’s $62 billion acquisition of U.K.-based Shire Pharmaceuticals in 2019 more than doubled Takeda’s revenue and significantly expanded its presence in the United States, positioning it as a formidable global competitor in the pharmaceutical industry.

“You make an acquisition like that—very large, very impactful—if strategically, you gain a lot from it,” Weber told CNBC’s Christine Tan in the latest episode of “Managing Asia.”

Now operating in approximately 80 countries, Takeda is focusing its efforts on high-impact therapeutic areas such as oncology, rare diseases, gastroenterology and neuroscience. As it enters its next phase of growth, the company is committed to scaling its innovation capabilities and reinforcing its role in shaping the future of global healthcare.

“You want to have a balanced pipeline, some areas are more risky than others. You don’t want to be on zero risk because then you will develop medicines without added value,” Weber said.

Watch the video above to learn more from Christophe Weber about Takeda’s transformation and how the company plans to stay ahead in an increasingly competitive market. 



Source

IBM is trying to rebound after results disappointed initially. What analysts and investors are saying
World

IBM is trying to rebound after results disappointed initially. What analysts and investors are saying

Analysts remain largely split on IBM ‘s future after the tech stalwart posted key metrics that flashed warning signs heading into 2026. While IBM reported a third-quarter earnings and revenue beat , analysts pointed to metrics below the surface headline beat that might indicate a worrisome near-term setup for the stock: namely, softness in IBM’s […]

Read More
The Beyond Meat fever highlights the risk of trying to ride the meme trade wave
World

The Beyond Meat fever highlights the risk of trying to ride the meme trade wave

The latest frenzy in Beyond Meat is offering a fresh reminder for investors chasing the latest viral stock — Riding the meme wave is fun, until it isn’t. The food company known for its plant-based burgers and sausages experienced monstrous gains of 128% Monday and 146% Tuesday. On Wednesday, the stock erased a triple-digit intraday […]

Read More
Kering shares pop as ‘sharp’ improvement at Gucci builds investor optimism
World

Kering shares pop as ‘sharp’ improvement at Gucci builds investor optimism

A woman wearing a Gucci belt and bag is seen during Paris Fashion Week in September 2018  Christian Vierig | Getty Images Shares of Gucci owner Kering closed up 8.7% on Thursday, hitting a 1-year high after the company’s sales decline narrowed and quarterly earnings beat estimates. The French luxury giant – whose brands include […]

Read More